InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,757.56
(
-0.06%
)
Post# of 8299
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

zino

Send PM Follow Ignore
Followers 335
Posts 19015
Boards Moderated 0
Alias Born 08/25/2007

zino

Re: zino post# 7554

Thursday, 09/14/2017 10:17:32 AM

Thursday, September 14, 2017 10:17:32 AM

Post# of 8299
Levosimendin Phase3 Results Still Have Value
Levosimendin demonstrated statistically significant reductions in two of three secondary endpoints including:
Reduction in low cardiac output syndrome (LCOS)
Reduction in postoperative use of secondary inotropes.

DONT LISTEN TO ME IM CANADIANNNNNNNN

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent TENX News
More TENX News
InvestorsHub NewsWire

Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Start posting your company's news
Only $200 per official company press release!